IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 71.12

Change

+0.48 (+0.68)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-20 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.82 (+0.56%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.23 (+0.33%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-0.04 (-0.04%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-0.64 (-0.69%)

USD 0.20B
IDNA iShares Genomics Immunology an..

+0.11 (+0.48%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.03 (+0.09%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.98 (-0.95%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.37 (-1.19%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.06 (+0.10%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.06 (-0.26%)

USD 6.89M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.22% 86% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.22% 86% B+ 82% B
Trailing 12 Months  
Capital Gain 2.90% 60% D- 43% F
Dividend Return 1.34% 88% B+ 23% F
Total Return 4.24% 62% D 33% F
Trailing 5 Years  
Capital Gain 33.39% 67% D+ 65% D
Dividend Return 8.88% 95% A 27% F
Total Return 42.27% 76% C+ 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.12% 48% F 47% F
Dividend Return 5.51% 57% F 45% F
Total Return 1.39% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 15.33% 71% C- 65% D
Risk Adjusted Return 35.94% 67% D+ 50% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike